ClinicalTrials.Veeva

Find clinical trials for Triple Negative Breast Cancer in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Sevilla, AN, ESP:

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR)

Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) wo ...

Enrolling
Triple Negative Breast Cancer
Drug: Nadunolimab
Drug: Carboplatin

Phase 1, Phase 2

Cantargia

Sevilla, Andalucía, Spain and 23 other locations

in patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC), refractory to ...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Sacituzumab govitecan
Drug: Granulocyte Colony-Stimulating Factor

Phase 2

MedSIR

Sevilla, Spain and 9 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Paclitaxel
Drug: Gemcitabine

Phase 3

Gilead Sciences
Gilead Sciences

Sevilla, Spain and 506 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Sevilla, Spain and 508 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Enrolling
Breast Cancer
Drug: Carboplatin
Drug: Nab-paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Sevilla, Spain and 273 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Sevilla, Spain and 192 other locations

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib [AZD1775]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Drug: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Sevilla, Spain and 140 other locations

III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Sevilla, Spain and 260 other locations

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer...

Enrolling
Triple Negative Breast Cancer
HER2-negative Breast Cancer
Drug: Sacituzumab govitecan
Drug: Cisplatin

Phase 3

German Breast Group (GBG) Research

Sevilla, Spain and 178 other locations

The purpose of this "first-in-human" study of FAZ053 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and an...

Active, not recruiting
Triple Negative Breast Cancer
Advanced Solid Tumors
Drug: PDR001
Drug: FAZ053

Phase 1

Novartis
Novartis

Sevilla, Andalucia, Spain and 11 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems